StreetInsider.com News Articles

Form DEFA14A Cigna Group

Fri, 13 Mar 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260313/26160158.html

Form DEFA14A Cigna Group

Fri, 13 Mar 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260313/26160158.html

Form DEF 14A Cigna Group For: Apr 22

Fri, 13 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260313/26160104.html

Form DEF 14A Cigna Group For: Apr 22

Fri, 13 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260313/26160104.html

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Investing.com -- Bernstein upgraded both Cigna Group and CVS Health Corp to Outperform in separate notes on Thursday, arguing that sweeping pharmacy benefit manager (PBM) reforms have removed a major overhang for the sector.

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event

Thu, 12 Mar 2026 09:00:55 -0400

Analyst Lance Wilkes said he is raising his Cigna rating to Outperform and lifting the price target to $358 from $307, noting that “PBM reform … will increase the CI multiple over time.”

He added that the combination of a new PBM transparency bill, an FTC settlement and Cigna’s previously announced PBM model changes enables the re-rating.

Bernstein is boosting its target multiple from

Bernstein SocGen Group Upgrades CIGNA (CI) to Outperform

Thu, 12 Mar 2026 08:04:44 -0400

Bernstein SocGen Group analyst Lance Wilkes upgraded CIGNA (NYSE: CI) from Market Perform to Outperform with a price target of $358.00 (from $307.00).

The analyst commented: "We are updating our earnings model with EPS estimates roughly the same for 2026, and modestly higher for 2027- 2030. We see PBM reform (PBM bill and FTC settlement) as clearing events for PBMs that will increase the CI multiple over time. Last quarter we noted that PBM multiples could re-rate to a higher level, but expected that would take more than just a PBM transparency bill to give investors confidence in a stable PBM

Bernstein SocGen Group Upgrades CIGNA (CI) to Outperform

Thu, 12 Mar 2026 08:04:44 -0400

Bernstein SocGen Group analyst Lance Wilkes upgraded CIGNA (NYSE: CI) from Market Perform to Outperform with a price target of $358.00 (from $307.00).

Form SCHEDULE 13G/A Cigna Group Filed by: VANGUARD GROUP INC

Thu, 05 Mar 2026 13:25:00 -0400

si-local-file:///var/storage/secattach/20260305/26117817.html

Form SCHEDULE 13G/A Cigna Group Filed by: VANGUARD GROUP INC

Thu, 05 Mar 2026 13:25:00 -0400

si-local-file:///var/storage/secattach/20260305/26117817.html

AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries